Novo Nordisk moved to stop two additional late-stage studies of the IL-6 inhibitor ziltivekimab after a data monitoring committee concluded the trials were unlikely to meet success criteria. The early terminations add to questions about the efficacy trajectory for the company’s IL-6 heart drug approach as it evaluates whether broader benefit signals can be substantiated.